unlocking in-house programs, page-4

And not to overlook the joint collaboration with Cambridge University, there are no less than six deal discussions underway in relation to - Phenomica target identification (ID) & validation.

At first I missed this piece of detail. Phenomica, however, could be an exciting development as it pursues 'target discovery against high value disease pathways'. Six deal discussions indicate a high level of international interest in the project. Bringing together the phylomer libraries, the scientific expertise of Cambridge University which I understand is highly regarded and potentially the money and methodology of Big Pharma.